ArticleBMC cancer2022

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.

Jie Mei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.